Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ESSA Pharma Inc. (EPIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 EFFECT Form EFFECT - Notice of Effectiveness:
10/03/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
08/08/2023 8-K Quarterly results
Docs: "ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/06/2023 3 Merendino Lauren (Director) has filed a Form 3 on ESSA Pharma Inc.
06/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ESSA Pharma Appoints Lauren Merendino to its Board of Directors South San Francisco, California and Vancouver, Canada, June 6, 2023 - ESSA Pharma Inc. , a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios. “Lauren’ s cross-functional expertise in guiding products through all stages of commercial development adds a valuable perspective that complements the skillset of our Board of Directors,” stated Richard M. Glickman, L.L.D. , Chairman of ESSA..."
05/09/2023 8-K Quarterly results
Docs: "ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
03/10/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
02/14/2023 SC 13G/A PFM Health Sciences, LP reports a 8.7% stake in ESSA Pharma Inc.
02/14/2023 SC 13G/A Soleus Capital, LLC reports a 8.8% stake in ESSA Pharma Inc.
02/14/2023 SC 13G/A Avidity Partners Management LP reports a 4.2% stake in ESSA Pharma Inc.
02/14/2023 SC 13G/A EVENTIDE ASSET MANAGEMENT, LLC reports a 0% stake in Essa Pharma Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2023 8-K Quarterly results
Docs: "ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022"
02/07/2023 10-Q Quarterly Report for the period ended December 31, 2022
01/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
01/05/2023 4 Parkinson David Ross (CEO) has filed a Form 4 on ESSA Pharma Inc.
Txns: Bought 21,367 shares @ $2.39, valued at $51.1k
Bought 3,067 shares @ $2.6, valued at $8k
01/05/2023 4 BERGER FRANKLIN M (Director) has filed a Form 4 on ESSA Pharma Inc.
Txns: Sold 25,000 shares @ $3, valued at $75k
Sold 32,000 shares @ $2.9, valued at $92.8k
Sold 50,000 shares @ $2.86, valued at $143k
Sold 50,000 shares @ $2.67, valued at $133.5k
Sold 43,617 shares @ $2.53, valued at $110.4k
Sold 37,889 shares @ $2.41, valued at $91.3k
Sold 34,334 shares @ $2.42, valued at $83.1k
01/05/2023 4 Wood David S. (CFO) has filed a Form 4 on ESSA Pharma Inc.
Txns: Bought 8,302 shares @ $2.6, valued at $21.6k
12/13/2022 8-K Quarterly results
12/13/2022 10-K Annual Report for the period ended September 30, 2022
11/10/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy